Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

醋酸甲羟孕酮：青春期阻断用 #1282

Open
wants to merge 3 commits into
base: master
Choose a base branch
from
Open

醋酸甲羟孕酮：青春期阻断用 #1282

Changes from all commits
Commits
Show all changes
3 commits
Select commit Hold shift + click to select a range
e57aa53
醋酸甲羟孕酮：青春期抑制用
Artoria2e5 Jan 18, 2025
d824e51
fixup! 换来源
Artoria2e5 Jan 18, 2025
8527d6e
fixup! Update content/zh-cn/docs/medicine/antiandrogen/medroxyprogest…
Artoria2e5 Jan 18, 2025
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
6 changes: 5 additions & 1 deletion content/zh-cn/docs/medicine/antiandrogen/medroxyprogesterone/index.md
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -10,6 +10,8 @@ description: 醋酸甲羟孕酮（Medroxyprogesterone Acetate），是一种类
醋酸甲羟孕酮（Medroxyprogesterone Acetate, MPA），是一种类固醇孕激素，具有抗促性腺激素作用，可以抑制体内雄激素水平。[^1] 在无法获取到 [醋酸环丙孕酮（色谱龙）]({{< ref cyproterone >}}) 时可作为替代品服用，但效果稍差。[^2] [^3] [^11]
关于 MPA 对睾酮水平的抑制作用，可参考[下文]({{< ref "#testosterone-suppression" >}})。

除作为 MtF HRT 的一部分抑制雄激素水平外，也可用于未成年人的青春期阻断治疗，相比 GnRH 类似物价格更低廉。[^14]旧时也用于治疗早发育，但由于不能抑制早发育对骨的影响，现已被 GnRH 类似物替代。[^15]用于青春期阻断无此考虑。

> **大中华区上市状况**

```csv
Expand Down Expand Up @@ -86,4 +88,6 @@ description: 醋酸甲羟孕酮（Medroxyprogesterone Acetate），是一种类
[^10]: 嘉義基督教醫院. 藥品詳細資訊：Medrone 5mg Tablets [EB/OL]. \[[資訊頁](https://www.cych.org.tw/pharm/searchdrugdetail.aspx?drug_serial=9622)] \[[仿單](https://www.cych.org.tw/pharm/%e4%bb%bf%e5%96%ae/PROVE-1080726.pdf)]
[^11]: Aly. An Introduction to Hormone Therapy for Transfeminine People [EB/OL]. *Transfeminine Science*, 2018. 译文：《[女性倾向跨性别者的激素治疗简介](https://tfsci.mtf.wiki/articles/transfem-intro/)》
[^12]: Meyer W J, Walker P A, Emory L E, et al. Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate [J]. *Fertility and Sterility*, 1985, 43(1): 102-109. DOI: [10.1016/S0015-0282(16)48326-3](https://www.sciencedirect.com/science/article/pii/S0015028216483263)
[^13]: Pfizer. Prescribing Information: PROVERA&reg; [EB/OL]. Drugs@FDA, 2024. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/011839s083lbl.pdf> 【[译文](https://tfsci.mtf.wiki/misc/provera/)】
[^13]: Pfizer. Prescribing Information: PROVERA&reg; [EB/OL]. Drugs@FDA, 2024. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/011839s083lbl.pdf> 【[译文](https://tfsci.mtf.wiki/misc/provera/)】
[^14]: Lynch, M. M., Khandheria, M. M., & Meyer, W. J. (2015). Retrospective Study of the Management of Childhood and Adolescent Gender Identity Disorder Using Medroxyprogesterone Acetate. International Journal of Transgenderism, 16(4), 201–208. https://doi.org/10.1080/15532739.2015.1080649
[^15]: Wheeler MD, Styne DM. Diagnosis and management of precocious puberty. Pediatr Clin North Am. 1990 Dec;37(6):1255-71. doi: [10.1016/s0031-3955(16)37010-9](https://doi.org/10.1016/S0031-3955(16)37010-9). PMID: 2147987.
Loading